Legal & General Group’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.1M | Buy |
33,072
+3,674
| +12% | +$797K | ﹤0.01% | 1308 |
|
|
2026
Q1 | $4.97M | Sell |
29,398
-7,304
| -20% | -$1.26M | ﹤0.01% | 1512 |
|
|
2025
Q4 | $6.7M | Sell |
36,702
-1,083
| -3% | -$151K | ﹤0.01% | 1409 |
|
|
2025
Q3 | $4.59M | Sell |
37,785
-2,460
| -6% | -$277K | ﹤0.01% | 1626 |
|
|
2025
Q2 | $4.2M | Buy |
40,245
+4,136
| +11% | +$438K | ﹤0.01% | 1630 |
|
|
2025
Q1 | $4.21M | Sell |
36,109
-261
| -0.7% | -$29.7K | ﹤0.01% | 1606 |
|
|
2024
Q4 | $3.08M | Buy |
36,370
+2,107
| +6% | +$194K | ﹤0.01% | 1802 |
|
|
2024
Q3 | $3.08M | Buy |
34,263
+614
| +2% | +$53.6K | ﹤0.01% | 1797 |
|
|
2024
Q2 | $2.71M | Buy |
33,649
+782
| +2% | +$57.9K | ﹤0.01% | 1806 |
|
|
2024
Q1 | $2.62M | Sell |
32,867
-150
| -0.5% | -$12.6K | ﹤0.01% | 1810 |
|
|
2023
Q4 | $2.63M | Sell |
33,017
-883
| -3% | -$59K | ﹤0.01% | 1810 |
|
|
2023
Q3 | $2.37M | Buy |
33,900
+576
| +2% | +$43.1K | ﹤0.01% | 1817 |
|
|
2023
Q2 | $2.39M | Buy |
33,324
+2,676
| +9% | +$197K | ﹤0.01% | 1838 |
|
|
2023
Q1 | $1.89M | Buy |
30,648
+3,637
| +13% | +$239K | ﹤0.01% | 1900 |
|
|
2022
Q4 | $2.08M | Buy |
27,011
+250
| +0.9% | +$14.9K | ﹤0.01% | 1867 |
|
|
2022
Q3 | $1.19M | Sell |
26,761
-1,771
| -6% | -$88.5K | ﹤0.01% | 2094 |
|
|
2022
Q2 | $1.09M | Buy |
28,532
+5,987
| +27% | +$189K | ﹤0.01% | 2131 |
|
|
2022
Q1 | $933K | Sell |
22,545
-14
| -0.1% | -$434 | ﹤0.01% | 2249 |
|
|
2021
Q4 | $852K | Buy |
22,559
+60
| +0.3% | +$2.21K | ﹤0.01% | 2274 |
|
|
2021
Q3 | $741K | Buy |
22,499
+4,752
| +27% | +$185K | ﹤0.01% | 2319 |
|
|
2021
Q2 | $1.2M | Sell |
17,747
-166
| -0.9% | -$9.96K | ﹤0.01% | 2163 |
|
|
2021
Q1 | $1.01M | Buy |
17,913
+2,031
| +13% | +$143K | ﹤0.01% | 2190 |
|
|
2020
Q4 | $1.29M | Sell |
15,882
-82
| -0.5% | -$6.13K | ﹤0.01% | 2040 |
|
|
2020
Q3 | $1.14M | Sell |
15,964
-1,220
| -7% | -$95.1K | ﹤0.01% | 1986 |
|
|
2020
Q2 | $1.41M | Buy |
17,184
+189
| +1% | +$14.5K | ﹤0.01% | 1873 |
|
|
2020
Q1 | $1M | Buy |
16,995
+9,068
| +114% | +$739K | ﹤0.01% | 1850 |
|
|
2019
Q4 | $820K | Buy |
7,927
+2,691
| +51% | +$109K | ﹤0.01% | 2116 |
|
|
2019
Q3 | $106K | Hold |
5,236
| – | – | ﹤0.01% | 2500 |
|
|
2019
Q2 | $135K | Buy |
+5,236
| New | +$105K | ﹤0.01% | 2441 |
|
|
2017
Q2 | – | Sell |
-1,158
| Closed | -$5K | – | 3358 |
|
|
2017
Q1 | $5K | Hold |
1,158
| – | – | ﹤0.01% | 3237 |
|
|
2016
Q4 | $8K | Buy |
+1,158
| New | +$8.13K | ﹤0.01% | 3246 |
|
Other funds holding AXSM
DTC
Legal & General Group's AXSM Position: Q2 2026 in Review
Legal & General Group increased its Axsome Therapeutics (AXSM) stake by 12% in Q2 2026, buying an estimated $797K and bringing the position to 33,072 shares worth $8.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1308.
Legal & General Group first reported a position in AXSM in Q4 2016 and has held it in 31 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Legal & General Group held 33,072 shares of Axsome Therapeutics worth $8.1M as of Q2 2026.
- Legal & General Group bought 3,674 Axsome Therapeutics shares in Q2 2026, an estimated $797K.
- Axsome Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1308 holding.
- Legal & General Group first reported a position in Axsome Therapeutics in Q4 2016 and has held it in 31 quarters since.
- 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.